Ameriprise
VYNE icon

Ameriprise’s VYNE Therapeutics VYNE Stock Holding History

Ameriprise’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,027
Closed -$7K – 4032
2022
Q2 		$7K Sell
1,027
-157
-13% -$1.32K ﹤0.01% 3869
2022
Q1 		$14K Sell
1,184
-20
-2% -$238 ﹤0.01% 3910
2021
Q4 		$22K Sell
1,204
-581
-33% -$12.5K ﹤0.01% 3926
2021
Q3 		$45K Buy
1,785
+1
+0.1% +$39 ﹤0.01% 3819
2021
Q2 		$113K Buy
1,784
+2
+0.1% +$158 ﹤0.01% 3810
2021
Q1 		$220K Sell
1,782
-877
-33% -$127K ﹤0.01% 3683
2020
Q4 		$303K Sell
2,659
-612
-19% -$76.9K ﹤0.01% 3500
2020
Q3 		$391K Sell
3,271
-805
-20% -$93.9K ﹤0.01% 3327
2020
Q2 		$520K Buy
4,076
+2,663
+188% +$361K ﹤0.01% 3185
2020
Q1 		$273K Sell
1,413
-10,333
-88% -$3.24M ﹤0.01% 3336
2019
Q4 		$3.92M Buy
+11,746
New +$3.92M ﹤0.01% 2374
2019
Q3 		– Sell
-236
Closed -$102K – 3774
2019
Q2 		$102K Sell
236
-13
-5% -$6.43K ﹤0.01% 3660
2019
Q1 		$141K Hold
249
– – ﹤0.01% 3605
2018
Q4 		$74K Buy
+249
New +$111K ﹤0.01% 3554

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Ameriprise's VYNE Position: Q3 2022 in Review

Ameriprise sold out of VYNE Therapeutics (VYNE) in Q3 2022, closing a stake of 1,027 shares — an estimated $7K sold.

Ameriprise first reported a position in VYNE in Q4 2018 and held it in 14 quarters. The position peaked at $3.92M in Q4 2019. 41 funds tracked by Wall St. Rank hold VYNE as of Q3 2022.

  • Ameriprise reported no remaining VYNE Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ameriprise sold 1,027 VYNE Therapeutics shares in Q3 2022, an estimated $7K.
  • Ameriprise first reported a position in VYNE Therapeutics in Q4 2018 and held it in 14 quarters.
  • Ameriprise's VYNE Therapeutics position peaked at $3.92M in Q4 2019.
  • 41 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2022.

Based on Ameriprise's 13F filing for Q3 2022, filed 14 Nov 2022.